# NCT02603432 (NCT02603432)

> A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02603432
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Urothelial Cancer
- Interventions: Avelumab; Best Supportive Care; Following the planned interim analysis for this study: Avelumab
- Enrollment: 700
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 76
- Podcasts: 43
- YouTube: 32
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02603432

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02603432", "email": "<work email>"}; the inbox owner confirms by the emailed link.